Zevra Therapeutics Announces Q2 2025 Earnings Report

Summary

Zevra Therapeutics (NASDAQ: ZVRA) will release its Q2 2025 earnings on August 12. Analysts predict earnings of $0.65 per share and revenue of $22.49 million. Previously, in Q1 2025, the company reported a loss of $0.06 EPS, exceeding estimates. ZVRA shares are currently trading at $11.23, down 0.2%. Institutional investors hold 35.03% of the stock. Recent analyst ratings include a price target increase from Cantor Fitzgerald to $29.00. The consensus rating for ZVRA is ‘buy’ with an average price target of $23.71. Market Beat

Impact Analysis

1. Business Overview Analysis: